Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
81 hedge funds and large institutions have $73.3M invested in Navidea Biopharmaceuticals Inc. in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 87 → 81 (-6)
11% less capital invested
Capital invested by funds: $82.4M → $73.3M (-$9.06M)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
99% less call options, than puts
Call options by funds: $59K | Put options by funds: $8.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$1.59M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$245K |
| 3 |
PM
Platinum Management
New York
|
+$173K |
| 4 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
+$172K |
| 5 |
Bank of New York Mellon
New York
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IG
ING Group
Amsterdam,
Netherlands
|
-$1.75M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$218K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$161K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$157K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$124K |
NAVB Hedge Fund Activity: Q3 2014 in Review
81 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2014, worth a combined $73.3M — down 11% from $82.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NAVB and 5 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 22 added.
The largest buyer was Commerzbank Aktiengesellschaft, adding an estimated $1.59M. The largest seller was ING Group, exiting entirely with an estimated $1.75M sold.
- 81 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2014, down from 87 in Q2 2014.
- Funds reported $73.3M of Navidea Biopharmaceuticals Inc. stock for Q3 2014, down 11% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2014 and 11 closed out, a net change of -6 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2014 was Commerzbank Aktiengesellschaft, an estimated $1.59M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2014 was ING Group, an estimated $1.75M sold.
Based on aggregated 13F filings for Q3 2014.